

Tofacitinib (Xeljanz® , Xeljanz XR®)

Selected References:

- Clowse M, et al. 2016. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. *Drug Saf*; 39(8):755-762.
- Fernández-Sánchez M, et al. 2021. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. *Birth Defects Res*; 113(17):1275-1279.
- Julsgaard M, et al. 2023. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. *Lancet Gastroenterol Hepatol*; 8:695-697.
- Mahadevan U, et al. 2018. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. *Inflammatory Bowel Diseases* 24(12):2494-2500.
- Mahadevan U, et al. 2019. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD Parenthood Project Working Group. *Gastroenterology* 156(5):1508-1524.
- Mahadevan U, et al. 2025. Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs. *Am J Gastroenterol*. Epub ahead of print. PMID: 4100213.
- Merren A, et al. 2015. THU0173 Pregnancy outcomes in the tofacitinib RA study database through April 2014. *Annals of the Rheumatic Diseases* 74:256-257.
- Mitrova K, et al. 2025. Assessing pregnancy and infant outcomes, cord blood and breast milk concentrations. *Clin Gastroenterol Hepatol*; 23:163-5.e3.
- Picardo S, Seow CH. 2019. A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: Biologic and oral small molecule therapy. *Drugs* 79(10):1053-1063.
- Rüegg L, et al. 2025. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. *Ann Rheum Dis*84:910-926.
- Selinger C, et al. 2024. Appropriateness of small molecule agents for patients with IBD of childbearing age - a RAND/UCLA appropriateness panel. *Therap Adv Gastroenterol* 2024;17:17562848241299737.
- U.S. Pharmaceuticals. Xeljanz/Xeljanz XR Prescribing Information. 2025. Available online at: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&type=pdf> Accessed 27 January 2026.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2026.

Tofacitinib (Xeljanz®, Xeljanz XR®)

Selected References:

- Aslinia F, et al. 2006. Megaloblastic anemia and other causes of macrocytosis. *Clinical Medicine & Research* 4.3:236-41.
- Benjamin RH, et al. 2025. National Birth Defects Prevention Study and the Birth Defects Study to Evaluate Pregnancy Exposures. Maternal folic acid supplement use, folate intake, and preterm birth among infants with spina bifida. *Birth Defects Res.* 117(12):e70008.
- Bortolus R., et al. 2021. Efficacy of 4.0 mg versus 0.4 mg folic acid supplementation on the reproductive outcomes: A randomized controlled trial. *Nutrients.* 13(12):4422.
- Centers for Disease Control and Prevention (CDC). 2025. Folic Acid Safety, Interactions, and Effects on Other Outcomes. Available at <https://www.cdc.gov/folic-acid/about/safety.html> [Accessed 01/2026].
- Centers for Disease Control and Prevention (CDC). 2025. Folic Acid: Sources and Recommended Intake. Available at <https://www.cdc.gov/folic-acid/about/intake-and-sources.html> [Accessed 01/2026].
- Centers for Disease Control and Prevention (CDC). 2025. MTHFR Gene Variant and Folic Acid Facts. Available at <https://www.cdc.gov/folic-acid/data-research/mthfr/> [Accessed 01/2026].
- Christian P. et al. 2010 Prenatal micronutrient supplementation and intellectual and motor function in early school-aged children in Nepal. *JAMA.* 304:2716-2723.
- Crider KS, et al. 2011. Folic acid food fortification-its history, effect, concerns, and future directions. *Nutrients;* 3(3):370-84.
- Cui Y, et al. 2021. Association of maternal pre-pregnancy dietary intake with adverse maternal and neonatal outcomes: A systematic review and meta-analysis of prospective studies. *Critical reviews in food science and nutrition,* 1-22.
- Dervla K, et al. 2012: Use of folic acid supplements and risk of cleft lip and palate in infants: A population-based cohort study. *Br J Gen Pract British Journal of General Practice* 62.600:466-72.
- Gaskins AJ, et al. 2012. The impact of dietary folate intake on reproductive function in premenopausal women: A prospective cohort study. *PLoS One* 7(9):e46276.
- Gaskins AJ, et al. 2014. Maternal prepregnancy folate intake and risk of spontaneous abortion and stillbirth. *Obstet Gynecol.* 124(1):23-31.
- Gildestad T, et al. 2020. Maternal use of folic acid and multivitamin supplements and infant risk of birth defects in Norway 1999-2013. *Br J Nutr.* 1-38.
- Gomez MG, et al. 2024. Global Neurosurgery at the 76th World Health Assembly (2023): First neurosurgery-driven resolution calls for micronutrient fortification to prevent spina bifida. *World Neurosurg.* S1878-8750(24)00101-3.
- Hodgetts VA, et al. 2015. Effectiveness of folic acid supplementation in pregnancy on reducing the risk of small-for-gestational age neonates: a population study, systematic review and meta-analysis. *BJOG.* 122:478-490.
- Ito K, et al. 2019. Association between maternal serum folate concentrations in the first trimester and the risk of

birth defects: The Hokkaido Study of Environment and Children's Health. *J Epidemiol.* 29(4):164-171.

- Levine SZ, et al. 2018. Association of maternal use of folic acid and multivitamin supplements in the periods before and during pregnancy with the risk of autism spectrum disorder in offspring. *JAMA Psychiatry.* 75(2):176-184. Liu C, et al. 2018. Supplementation of folic acid in pregnancy and the risk of preeclampsia and gestational hypertension: a meta-analysis. *Arch Gynecol Obstet.*; 298:697-704.
- Liu X, et al. 2023. Folic acid supplements and perinatal mortality in China. *Front Nutr.* 10:1281971.
- Li X, et al. 2023. Effects of folic acid and folic acid plus zinc supplements on the sperm characteristics and pregnancy outcomes of infertile men: A systematic review and meta-analysis. *Heliyon.* 13;9(7):e18224.
- Mohseni GK, et al. 2025. Association of spontaneous abortion with dietary folate intake in individuals with different genotypes of FTO gene. *BMC Pregnancy Childbirth.* 25(1):961.
- National Institutes of Health (NIH) Office of Dietary Supplements. 2022. Folate Fact Sheet for Consumers. <https://ods.od.nih.gov/factsheets/Folate-Consumer/> [Accessed 01/2026].
- National Institutes of Health (NIH) Office of Dietary Supplements. 2022. Folate Fact Sheet for Health Professionals. <https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/> [Accessed /01/2026].
- Pittschieler S, et al. 2008. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. *J Neurol.* 255(12):1926-31.
- Raghavan R, et al. 2018. Maternal multivitamin intake, plasma folate and vitamin B12 levels and autism spectrum disorder risk in offspring. *Paediatr Perinat Epidemiol.* 32(1):100-111.
- Schmidt RJ, et al. 2012. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. *Am J Clin Nutr.* 96(1):80-9.
- Surén P, et al. 2013. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. *JAMA.* 309(6):570-7.
- Toriello H. 2011. Policy Statement on Folic Acid and Neural Tube Defects. *Genet Med* 13.6: 593-96.
- U.S. Food and Drug Administration (FDA). 2024. Folate and Folic Acid on the Nutrition and Supplement Facts Labels. <https://www.fda.gov/food/nutrition-facts-label/folate-and-folic-acid-nutrition-and-supplement-facts-labels> [Accessed 01/2026].
- Wang G, et al. 2016. Association between maternal pregnancy body mass index and plasma folate concentrations with child metabolic health. *JAMA Pediatr.* 170(8):e160845.
- Wantong H, et al. 2024. Periconceptional supplementation with folic acid or multiple micronutrients containing folic acid and the risk for hypertensive disorders in pregnancy. *Med Princ Pract.* 33(6):578-586.
- Wen S, et al. 2016. Folic acid supplementation in pregnancy and the risk of pre-eclampsia—A cohort study. *PLoS ONE* 11.2 .
- Wong W, et al. 2002. Effects of folic acid and zinc sulfate on male factor subfertility: A double-blind, randomized, placebo-controlled trial. *Fertility and Sterility* 77:491-8.
- World Health Organization (WHO). 2009. Recommendations on wheat and maize flour fortification: meeting report - interim consensus statement. http://www.who.int/nutrition/publications/micronutrients/wheat_maize_fortification/en/ [Accessed 01/2026].
- Young SS, et al. 2008. The association of folate, zinc and antioxidant intake with sperm aneuploidy in healthy non-smoking men. *Hum. Reprod.* 23(5):1014-1022.
- Zhang M, et al. 2025. Duration of folic acid supplementation and adverse pregnancy outcomes: A prospective multicenter cohort study in China. *Nutrients.* 18(1):81.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2026.

Tofacitinib (Xeljanz®, Xeljanz XR®)

Selected References:

- Baheiraei A, et al. 2001. Effects of progestogen-only contraceptives on breast-feeding and infant growth *Int J Gynaecol Obstet*, 74; 203-205.
- Borgatta L, et al. 2002. Pregnancies diagnosed during Depo- Provera use. *Contraception*. Sep;66(3):169-72.
- Callahan R et al. 2015. Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: A systemic review. *Contraception* 92(6):514-522.
- Dahlberg K. 1982. Some effects of depotmedroxyprogesterone acetate (DMPA): Observations in the nursing infant and in the long-term user. *Int J Gynaecol Obstet* 20:43-48.
- Deshmukh P, Antell K, Brown EJ. 2017. Contraception Update: Progestin-Only Implants and Injections. *FP Essent.* 462:25-29.
- Gray RH and Pardthaisong T. 1991. In utero exposure to steroid contraceptives and outcome of pregnancy. *Am J Epidemiol* 134:795-803.
- Gray RH, Pardthaisong T. 1991. In utero exposure to steroid contraceptives and survival during infancy. *Am J Epidemiol*; 134:804-811.
- Gu YQ, et al. 2004. Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. *J Clin Endocrinol Metab*. 89(5):2254-62.
- Hogue CJ. 1991. Invited commentary: the contraceptive technology tightrope. *Am J Epidemiol* 134: 812-815; author response 816-817.
- Jaffe B et al. 1990. Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate. *Paediatr Perinat Epidemiol* 4:184-195.
- Jimenez J et al. 1984. Long-term follow-up of children breast-fed by mothers

receiving depotmedroxyprogesterone acetate. *Contraception* 30:523-533.

- Koetsawang S, et al. 1982. Transfer of contraceptive steroids in milk of women using long-acting gestagens. *Contraception* 25:321- 331.
- Pardthaisong T, et al. 1992. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. *Contraception* 45:313-324.
- Pardthaisong T, Gray R. 1988. Steroid contraceptive use and pregnancy outcome. *Teratology* 38:51-58.
- PDR Entry for: Depo-Provera Contraceptive Injection. 2016. Pharmacia and Upjohn Company LLC.
- Phillips SJ, et al. 2016. Progestogen-only contraceptive use among breastfeeding women: A systematic review. *Contraception*; 94:226-252.
- Ratchanon S and Taneepanichskul S. 2000. Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women. *Obstetrics & Gynecology* 96(6):926-928.
- Saxena BN et al. 1977. Levels of contraceptive steroids in breast milk and plasma of lactating women. *Contraception* 16:605-613.
- Virutamasen P et al. 1996. Pharmacodynamic effects of depot-lprogesterone acetate (DMPA) administered to lactating women on their male infants. *Contraception* 54:153-157.
- World Health Organization. 2016. Resource chart medical eligibility contraceptives – FHI 360. (n.d.). Available at: <https://www.fhi360.org/sites/default/files/media/documents/resource-chart-medical-eligibility-contraceptives-english.pdf>. Accessed 13 January 2026.
- Yovich JL, et al. 1988. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. *Teratology* 38:135-144.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2026.

Tofacitinib (Xeljanz® , Xeljanz XR®)

Selected References:

- Bodkin CL, et al. 2005. OnabotulinumtoxinA therapy during pregnancy. *Mov Disord* 20(8): 1081-1082.

- Briggs J, et al. 2005. Drugs in pregnancy and lactation, 7th Ed. 174-175. Lippincott Williams & Wilkins: Philadelphia.
- Brin MF, et al. 2016. Pregnancy outcomes following exposure to onabotulinumtoxinA. *Pharmacoepidemiology and Drug Safety*. 25: 179-187.
- Brin, MF, et al 2023. Pregnancy outcomes in patients exposed to onabotulinumtoxinA treatment. *Neurology*. 101: e103-e113.
- Cardon BR, Smith ME, Cerrati EW. 2021 May-June. Case Series of Botulinum Toxin Administered to Pregnant Patients and Review of the Literature. *Facial Plast Surg Aesthet Med*. 23(3):187-190. De Oliveira Monteiro E. 2006. Botulinum toxin and pregnancy. *Skinmed* 5(6): 308.
- Li Yim and Weir CR. 2010. Botulinum toxin and pregnancy - cautionary tale. *Strabismus* 18(2): 65-66.
- Morgan JC, et al. 2006. Botulinum toxin A during pregnancy: a survey of treating physicians. *J Neurol Neurosurg Psychiatry* 77 (1) 117-119.
- Newman W.J., et al 2004. OnabotulinumtoxinA therapy during pregnancy. *Mov Disord* 19(11): 1384-1385.
- Polo JM, et al. 1996. Botulism and pregnancy. *Lancet* 348: 195.
- Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. *Mil Med*. 2014 Jun;179(6):e703-4.
- St. Clair EH, et al. 1975. Observations of an infant born to a mother with botulism. *J Pediatr* 87: 658.
- Wataganara T, et al. 2009. Treatment of severe achalasia during pregnancy with esophagoscopy injection of botulinum toxin A: a case report. *J Perinatol* 29(9): 639.
- Wong HT, et al. 2020. OnabotulinumtoxinA for chronic migraine during pregnancy: a real-world experience on 45 patients. *J Headache Pain*. 21(1):129.
- Wong HT, et al. 2025. OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull. *Cephalalgia* 45(5):3331024251327387.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2026.

Tofacitinib (Xeljanz[®], Xeljanz XR[®])

Selected References:

- Alembic Pharmaceuticals Inc. 2017. Metoprolol tartrate product labeling. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24837d82-0f3f-4482-9af0-31e5f675c30f>. Accessed 27 Jan 2026.
- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. *Pediatrics*; 138(3). pii:e20160731.
- Battarbee AN, et al. 2020. Chronic hypertension in pregnancy. *Am J Obstet Gynecol*; 222(6):532-541.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf*. 20(2):138-145.
- Duan L, et al. 2017. β -Blocker exposure in pregnancy and risk of fetal cardiac anomalies. *JAMA Intern Med*. 177(6): 885-887.
- Duan L, et al. 2018. Beta-blocker subtypes and risk of low birth weight in newborns. *J Clin Hypertens* 20(11):1603-1609.
- Firoz T, et al. 2014. Community Level Interventions for Pre-Eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. *BJOG*. 121(10):1210-1218.
- Kulas J et al. 1984. Atenolol and metoprolol. A comparison of their excretion into human breast milk. *Acta Obstet Gynecol Scand Suppl*. 118: 65-69.
- Lindeberg S et al. 1984. Disposition of the adrenergic blocker metoprolol in the late-pregnant woman, the amniotic fluid, the cord blood and the neonate. *Acta Obstet Gynecol Scand Suppl*. 118: 61-64.
- Ruys TP, et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. *Int J Cardiol*. 15. 177(1):124-8.
- Sandstrom B, Regardh CG. 1980. Metoprolol excretion in breast milk. *Br J Clin Pharmacol*. 9: 518-519.
- Tamirisa KP, et al. 2022. Arrhythmias in Pregnancy. *JACC Clin Electrophysiol*. 8(1):120-135.
- Tanaka K, 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. *Circ J*. 80(10):2221-2226.
- Welzel T, et al. 2021. Intrauterine Growth Retardation in Pregnant Women with Long QT Syndrome Treated with Beta-Receptor Blockers. *Neonatology*. 118(4):406-415.
- Wichman K et al. 1984. A placebo controlled trial of metoprolol in the treatment of hypertension in pregnancy. *Scand J Clin Lab Invest Suppl*. 169: 90-95.
- Xie RH, et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. *BJOG*. 121(9):1090-1096.
- Yakoob MY, et al. 2013. The risk of congenital malformations associated with exposure to β -blockers in pregnancy: a meta-analysis. *Hypertension* 62(2):375-381.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, January 1, 2026.